Moreover, 21.8% of patients with chronic hepatitis C had positive ANA and lower sustained virological response to interferon-based therapy, while the incidence of cirrhosis, hepatocellular carcinoma, and mortality showed no significant difference from those with negative ANA [7]. This evidence concerns the gene BTG3 and hepatocellular carcinoma.